Great data here from The Leukemia & Lymphoma Society on antibody response to #COVID19 vaccines for patients with blood cancers! Myeloid malignancies have >90%, Lymphoid may drop 25%. cell.com/cancer-cell/fu…

1/n: And BOOM!!! Our immune correlates of protection manuscript is now fully peer reviewed!

Wondering who is considered #immunocompromised in the eyes of #CDC #ACIP following yesterday’s #FDA authorization of a 3rd dose of Pfizer or Moderna #COVID19 #vaccine for this group?

My personal, by no means exhaustive highlights of #lungcancer @ other #thoraciccancer abstracts for upcoming #ESMO21. Pls feel free to add/share/RT/comment. Apologies if I miss any. Looking forward to the presentations!! OncoAlert ESMO - Eur. Oncology ASCO The ASCO Post IASLC #LCSM Chat #some

📣Global Oncology Opportunity We are excited to launch our Project ECHO Global Oncology Tumor Board 2021-22 Dartmouth Health | Inactive: A unique platform that leverages learning, training and practice support to give voice to healthcare knowledge around the world Registration is free

Important work from Dr. Doreen Ezeife MD, MSc, FRCPC & team. Doing more testing up-front with liquid biopsy + tissue NGS actually SAVES the health system money, and more importantly gets patients the best first-line treatment. Time to update our standard workflow... Marina Garassino

Presented at #ESMO21, first concrete results regarding #COVID19vaccine in #cancer patients: robust data proves efficacy, safety and that a 3rd booster dose may improve immune response in this population. Aɴᴛᴏɴɪᴏ Pᴀssᴀʀᴏ #visualabstract 👉 ow.ly/u6bR50GdAwI #COVID19nCancer

Excited for the opportunity to participate in the Early Career Immunology series next Tuesday at 12pm ET. I’ll be talking on unpublished new models of peripheral T cell tolerance and how immune checkpoint blockade can lead to immunopathology.

Work from Mary Clyde and wee chua !

CDKN2A LOF as a predictor of ICB resistance in NSCLC: nature.com/articles/s4159….

Interesting study ⁦Clinical Cancer Research⁩ shows high-dose steroids (>60mg pred) for early irAEs (within 8wks antiPD1) for melanoma is assoc with poorer: - post-irAE PFS - post-irAE OS validated by multinational cohort& confirmed by sensitivity analysis ⁦ clincancerres.aacrjournals.org/content/27/21/…

Join me, Marina Garassino & Sherin Rouhani, MD PhD for a webinar on the difference btwn basic science & clinical science with respect to COVID Vax and #LungCancer. Register at the link below! OPEN TO ALL - gift card raffle for all attendees! #lcsm EGFR Resisters UChicagoCancerCenter UCM Cancer Center OCECHE

📣 #MedTwitter #FDA granted emerg use auth to AZ long-acting Ab cocktail (Evusheld) for #COVID19 PRE-exposure prophylaxis in mod-severe immunocompromised (age 12+ & 40+ kg). Two IM injections, may repeat q6 mos. At least 2w post vax. ⚠️ Not PEP/treatment fda.gov/media/154701/d…

So excited to share the preprint of our study looking at mechanisms of progression to severe COVID! Couldn’t have done it without co-first authors @HowellJollyBody and @jontrujilloNM, Jovian Yu, MD, MS & entire team. #TeamScience for the win!

Here's what the data looked like for people who got Pfizer: 7/16

More data emerging emphasizing the importance of boosters against Omicron - 2 doses of mRNA vax are good against original or delta strains, but for omicron the neutralization ability after 2 doses isn't great. Omicron neutralization improves substantially after booster!

Patient-centered summary of the #CheckMate816 neoadjuvant chemo-immunotherapy clinical trial. This is a new treatment for patients with stage 1-3 non-small-cell lung cancer that can be removed by surgery. The summary may be useful for clinicians & patients. #lcsm LUNGevity Foundation

So proud of Kerry Reynolds and her amazing team Mass General Cancer Center for pioneering the IO complications inpt team 5 years ago. Has been the foundation on which multi-specialty expertise in IO tox has been built across our general hospital! #TrailBlazer #WIO 🙌science.org/content/articl…

Proud to present our work, now online JCO Precision Oncology: "STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small Cell Lung Cancer" ascopubs.org/doi/full/10.12… So thankful for our numerous collaborators across multiple departments and institutions Tweetorial 👇

👀 See what’s popular this week in #JCOPO: STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage NSCLC ➡️ fal.cn/3v5BT #lcsm @seanpitroda Liam F. Spurr, MD @sgutiontov Aditya Juloori Michael Sargent Binkley Sherin Rouhani, MD PhD Bill Loo MD PhD ⚡️☢️ Rohan Katipally